查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2100418

急性細菌性皮膚及結構感染疾病市場－2026-2032年全球市場預測

Acute Bacterial Skin & Skin Structure Infection Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，急性細菌性皮膚和皮膚結構感染疾病市場將成長至 47.9 億美元，複合年成長率為 6.41%。

主要市場統計數據
基準年 2025 31億美元
預計年份：2026年 32.8億美元
預測年份 2032 47.9億美元
複合年成長率 (%) 6.41%

急性細菌性皮膚及皮膚結構感染疾病（ABSSSIs）因其症狀範圍廣泛（從常見到嚴重），包括蜂窩組織炎、丹毒、傷口感染和嚴重皮膚膿腫，仍然是感染疾病控制領域的重中之重。這些感染疾病，尤其是當涉及抗藥性金黃色葡萄球菌（MRSA）、BETA-溶血性鏈球菌或多種細菌性傷口病原體時，會對急診、門診、外科和合理用藥計畫造成持續的負擔。臨床目標不再局限於快速控制症狀；醫療系統越來越重視早期觀察分層、基於微生物學的治療、縮短住院時間、縮短靜脈注射向口服給藥的過渡時間以及預防復發。

急性細菌性皮膚及皮膚結構感染（ABSSSI）的治療模式受到全球抗生素抗藥性、糖尿病盛行率上升、人口老化、肥胖、術後傷口併發症、創傷相關感染疾病以及醫療相關感染風險等因素的影響。基於指引的治療強調快速診斷、必要時進行切開引流、合理選擇經驗性抗生素、在規定的臨床時間範圍內進行重新評估，並在基於微生物學或臨床證據，當可以採用更有限的治療方案時，逐步減少抗生素用量。同時，保險公司和醫院正在加速推廣門診靜脈抗生素治療、長效抗生素方案、快速診斷方法以及能夠減少不必要的住院治療且不影響安全性的診療路徑。

對於製藥、診斷、醫療保健和公共衛生領域的相關人員，急性細菌性皮膚及皮膚結構感染（ABSSSI）是一個具有重要策略意義的治療領域，創新必須與合理使用抗生素、實證處方和可衡量的臨床結果一致。對「急性細菌性皮膚感染疾病的治療」、「ABSSSI的抗生素」、「抗甲氧西林金黃色葡萄球菌（MRSA）皮膚感染疾病」、「蜂窩組織炎炎的搜尋」、「傷口感染疾病的治療」和「抗生素抗藥性」等關鍵字的搜尋需求，反映出臨床、監管和商業領域的相關人員對可靠的決策資訊的需求日益成長。

ABSSSI領域的變革性變化

在急性細菌性皮膚及皮膚結構感染（ABSSSI）領域，一場根本性的轉變正在發生，即從廣泛的住院治療轉向基於精準醫療的臨床最佳化治療。傳統上，中度至重度皮膚感染疾病，尤其是疑似抗甲氧西林金黃色葡萄球菌（MRSA）感染的患者，通常需要住院接受靜脈注射抗生素治療。如今，臨床醫生正在改進他們的診療實踐，採用結構化的嚴重程度評估、合併症篩檢和早期介入標準，以確定患者是否可以安全地在門診或觀察下進行管理。此轉變得益於創傷護理方案的改善、門診靜脈輸液服務的增加，以及旨在減少重複住院次數並同時維持有效藥物暴露的治療方法。

人工智慧對ABSSSI護理的累積影響

人工智慧 (AI) 正開始影響 ABSSSI 護理的各個方面，包括診斷、分診、治療選擇、營運效率和監測。在臨床實踐中，AI 驅動的影像分析可以利用標準化的照片記錄，輔助評估紅斑進展、傷口大小、壞死、滲出和癒合進展。雖然臨床醫生的評估仍然至關重要，但演算法驅動的傷口和皮膚評估可以提高評估的一致性，尤其是在遠端醫療、急診分診、遠端患者監護和出院後追蹤方面。

關於ABSSSI的關鍵區域見解

亞太地區人口密度高、門診病人就診量大、微生物檢測資源分配不均，且糖尿病和創傷相關傷口感染疾病負擔沉重，因此該地區對急性細菌性皮膚及軟組織感染（ABSSSI）至關重要。日本、韓國和澳洲等醫療衛生體系完善的國家優先考慮合理使用抗生素、感染控制以及基於循證醫學的耐甲氧西林金黃色葡萄球菌（MRSA）預防療法，而新興經濟體則繼續優先考慮醫療服務的可及性、可負擔性以及初級保健診斷能力的提升。亞太地區許多地方正透過國家行動計畫和區域實驗室網路擴大抗菌藥物抗藥性監測，但檢測能力的差異影響著針對特定病原體的治療和抗生素降減重治療的實施速度。

關於ABSSSI的關鍵小組見解

雖然北約成員國並非醫療衛生集團，但它們擁有許多先進的醫療衛生體系，其中軍事醫學、創傷護理、戰場感染控制和緊急應變計畫與急性細菌性皮膚及軟組織感染（ABSSSI）的管理密切相關。從戰鬥傷口感染處理方案、抗生素供應保障、感染預防物流和大規模傷亡緊急準備中汲取的經驗教訓，可以應用於更廣泛的複雜皮膚及軟組織感染疾病應對準備工作。七國集團（G7）國家通常在臨床研究能力、監管標準化、藥物安全監測、合理使用抗生素以及獲得先進診斷和治療方面處於主導地位。它們的ABSSSI策略日益強調以價值為導向的醫療、門診護理模式、抗生素療效和安全性的真實世界數據，以及合理使用頻譜抗生素。

ABSSSI 的關鍵國家概況

中國ABSSSI（急性細菌性皮膚及皮膚結構感染）的防治環境受其龐大的醫療規模、不斷擴大的合理用藥政策以及對醫院感染控制和診斷技術的持續投入所塑造。美國擁有高度發達的ABSSSI防治環境，這得益於對社區獲得性耐甲氧西林金黃色葡萄球菌（MRSA）的認知、急診科的治療途徑、門診靜脈抗生素治療以及對合理用藥的高期望。日本擁有成熟的臨床體系和強力的法律規範，人口老化導致皮膚和創傷護理需求增加，並實施嚴格的抗生素管治。印度由於人口眾多、糖尿病盛行率高、創傷暴露風險高以及對抗生素抗藥性的擔憂，面臨沉重的ABSSSI負擔，因此，提高診斷可及性和合理使用抗生素是當務之急。

關於ABSSSI，為業界領導者提供的實用建議

產業領導者應優先考慮抗菌藥物穩定症候群 (ABSSSI) 的應對措施，使臨床創新與合理使用抗生素和實際醫療服務相結合。在治療藥物研發過程中，應重點關注病原體覆蓋範圍、安全性、給藥便捷性、組織穿透性、用藥依從性以及是否適用於門診治療模式等方面的明確差異化。抗菌藥物的定位必須有充分的證據、微生物學依據和患者選擇指南支持，因為不必要的頻譜抗生素使用會導致抗藥性的產生。

調查方法

本執行摘要採用系統性的二手研究途徑，利用檢驗的臨床、監管、流行病學和公共衛生資訊來源編寫而成。分析整合了來自感染疾病治療指南、抗菌藥物抗藥性監測計畫、ABSSSI臨床試驗監管指南、同行評審文獻、醫院抗菌藥物合理使用框架以及與糖尿病、傷口感染、耐甲氧西林金黃色葡萄球菌（MRSA）、蜂窩組織炎、膿腫管理和門診抗菌治療相關的公共衛生數據的證據。

結論

急性細菌性皮膚及結構性皮膚感染疾病（ABSSSI）的治療正從傳統的抗生素治療轉向以合理使用抗生素為基礎的多學科、技術驅動型醫療保健模式。抗生素抗藥性的日益增強、抗甲氧西林金黃色葡萄球菌（MRSA）感染風險持續存在、糖尿病相關傷口併發症、人口老化以及減少不必要住院治療的壓力，正在重塑臨床醫生診斷、分診和治療ABSSSI的方式。在有效抗生素治療與快速診斷、優質創傷護理、完善的門診醫療系統和系統性追蹤相結合的領域，已取得最顯著的進展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：急性細菌性皮膚和結構性皮膚感染疾病市場：依最終用戶分類

  • 門診手術中心
  • 家庭醫療保健環境
  • 醫院

第8章：急性細菌性皮膚和結構性皮膚感染疾病市場：依分銷管道分類

  • 離線
  • 線上

第9章：急性細菌性皮膚和結構性皮膚感染疾病市場：依感染類型分類

  • 蜂窩組織炎
  • 傷口感染疾病
  • 主要皮膚膿腫
  • 感染性潰瘍

第10章：急性細菌性皮膚和結構感染疾病市場：依致病病原體分類

  • 革蘭氏陽性菌
  • 革蘭氏陰性菌
  • 混合物

第11章：急性細菌性皮膚和結構性皮膚感染疾病市場：按藥物類別分類

  • 醣肽抗生素
  • 醣肽抗生素
  • Oxazolidinone系列
  • 脂肽

第12章：急性細菌性皮膚和結構性皮膚感染疾病市場：依給藥途徑分類

  • 靜脈輸液療法
  • 口服療法
  • 治療方案由靜脈注射逐步過渡到口服給藥。

第13章：急性細菌性皮膚和結構性皮膚感染疾病市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章：急性細菌性皮膚和結構性皮膚感染疾病市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章：急性細菌性皮膚感染和結構性皮膚感染疾病市場：按國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Advanz Pharma Corp. Limited
  • Almirall, SA
  • Astellas Pharma Inc.
  • Basilea Pharmaceutica Ltd.
  • Bayer Aktiengesellschaft
  • Cumberland Pharmaceuticals Inc.
  • Dr. Reddy's Laboratories Limited
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Iterum Therapeutics plc
  • Lupin Limited
  • Melinta Therapeutics, LLC
  • Merck KGaA
  • Nabriva Therapeutics plc
  • Paratek Pharmaceuticals, Inc.
  • Sandoz Group AG
  • Shionogi & Co., Ltd.
  • Spero Therapeutics, Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Venatorx Pharmaceuticals, Inc.
  • Viatris Inc.
  • Xellia Pharmaceuticals ApS
Product Code: MRR-B16853776E4F

The Acute Bacterial Skin & Skin Structure Infection Market is projected to grow by USD 4.79 billion at a CAGR of 6.41% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.10 billion
Estimated Year [2026] USD 3.28 billion
Forecast Year [2032] USD 4.79 billion
CAGR (%) 6.41%

Acute bacterial skin and skin structure infection (ABSSSI) remains a high-priority infectious disease area because it spans common and potentially severe presentations, including cellulitis, erysipelas, wound infection, and major cutaneous abscesses. These infections place sustained pressure on emergency departments, outpatient clinics, surgical services, and antimicrobial stewardship programs, particularly when methicillin-resistant Staphylococcus aureus (MRSA), beta-hemolytic streptococci, or polymicrobial wound pathogens are involved. The clinical objective is no longer limited to rapid symptom control; health systems are increasingly focused on early risk stratification, microbiology-guided therapy, reduced hospital exposure, shorter intravenous-to-oral transitions, and prevention of recurrence.

The ABSSSI treatment landscape is shaped by the global burden of antimicrobial resistance, rising diabetes prevalence, aging populations, obesity, post-surgical wound complications, trauma-related infections, and healthcare-associated transmission risks. Guideline-based care emphasizes prompt diagnosis, incision and drainage when indicated, appropriate empiric antibiotic selection, reassessment within defined clinical windows, and de-escalation once microbiological or clinical evidence supports narrower therapy. At the same time, payer and hospital priorities are accelerating adoption of outpatient parenteral antimicrobial therapy, long-acting antibiotic regimens, rapid diagnostics, and care pathways that reduce avoidable admissions without compromising safety.

For stakeholders across pharmaceuticals, diagnostics, healthcare delivery, and public health, ABSSSI is a strategically important therapeutic domain where innovation must align with antimicrobial stewardship, evidence-based prescribing, and measurable clinical outcomes. Search demand around acute bacterial skin infection treatment, ABSSSI antibiotics, MRSA skin infection, cellulitis management, wound infection therapy, and antimicrobial resistance reflects the growing need for reliable, decision-ready intelligence across clinical, regulatory, and commercial audiences.

Transformative Shifts in the ABSSSI Landscape

The ABSSSI landscape is undergoing a fundamental shift from broad inpatient management toward precision-enabled, site-of-care-optimized treatment. Historically, moderate-to-severe skin infections often triggered hospitalization for intravenous antibiotics, particularly when MRSA risk was suspected. Current practice is evolving as clinicians use structured severity assessment, comorbidity screening, and early response criteria to determine whether patients can be managed safely in outpatient or observation settings. This shift is supported by improved wound care protocols, greater use of ambulatory infusion services, and therapies designed to maintain effective exposure while reducing repeated hospital visits.

Antimicrobial resistance is another defining force. Surveillance programs consistently identify Staphylococcus aureus, including MRSA, and Streptococcus pyogenes as core pathogens in ABSSSI, while diabetic foot infections, surgical site infections, and traumatic wounds may involve gram-negative and anaerobic organisms. This pathogen diversity has strengthened the role of local antibiograms, culture-based confirmation in purulent or complicated infections, and stewardship interventions that discourage unnecessary broad-spectrum use. Regulatory and clinical trial frameworks have also become more standardized, with early clinical response endpoints and lesion-size assessments used to evaluate therapeutic benefit in ABSSSI studies.

Patient expectations and health system economics are also reshaping care. Convenience, adherence, fewer treatment failures, and reduced readmission risk are increasingly important differentiators. Digital follow-up, home-based wound monitoring, and multidisciplinary care models involving infectious disease specialists, surgeons, pharmacists, diabetes teams, and nursing services are becoming more relevant. Together, these changes are transforming ABSSSI from a relatively protocol-driven antibiotic category into an integrated care pathway focused on diagnosis, treatment optimization, resistance containment, and patient-centered delivery.

Cumulative Impact of Artificial Intelligence on ABSSSI Care

Artificial intelligence is beginning to influence ABSSSI care across diagnosis, triage, treatment selection, operational efficiency, and surveillance. In clinical settings, AI-enabled image analysis has the potential to support assessment of erythema progression, wound dimensions, necrosis, drainage, and healing trajectory using standardized photographic documentation. While clinician evaluation remains essential, algorithm-assisted wound and skin assessment can improve consistency, especially in telemedicine, emergency triage, remote patient monitoring, and post-discharge follow-up.

AI can also strengthen antimicrobial stewardship by integrating electronic health record data, local resistance patterns, allergy history, renal function, prior antibiotic exposure, microbiology results, and comorbidity profiles to support more appropriate empiric therapy and earlier de-escalation. Predictive analytics may help identify patients at higher risk of treatment failure, abscess recurrence, sepsis, hospitalization, or readmission. These use cases are particularly relevant in ABSSSI because early clinical response is a critical marker of treatment success and delayed escalation can worsen outcomes.

At the system level, AI can enhance syndromic surveillance by detecting clusters of skin and soft tissue infections, monitoring MRSA trends, and identifying unusual resistance signals. Natural language processing can extract clinical features from unstructured notes, improving real-world evidence generation on cellulitis, abscesses, wound infections, and antibiotic utilization. However, the cumulative impact of AI will depend on validated datasets, bias mitigation across skin tones and populations, integration into clinician workflows, cybersecurity safeguards, and transparent governance. In ABSSSI, the most valuable AI applications are likely to be those that improve diagnostic confidence, reduce unnecessary antibiotic exposure, and enable safer outpatient management.

Key Regional Insights for ABSSSI

Asia-Pacific is a critical region for ABSSSI due to large population density, high outpatient volumes, variable access to microbiology testing, and the substantial burden of diabetes and trauma-related wound infections. Countries with advanced healthcare systems, including Japan, South Korea, and Australia, emphasize antimicrobial stewardship, hospital infection control, and evidence-based use of anti-MRSA therapies, while emerging economies continue to prioritize access, affordability, and improved primary care diagnosis. In many Asia-Pacific settings, antimicrobial resistance surveillance is expanding through national action plans and regional laboratory networks, but disparities in laboratory capacity influence the speed of pathogen-directed treatment and antibiotic de-escalation.

Europe demonstrates a guideline-driven approach shaped by national antimicrobial resistance action plans, hospital stewardship committees, and coordinated surveillance. Western European countries generally maintain strong diagnostic and prescribing governance, while regional variations remain in access to specialized wound care, outpatient infusion services, and rapid microbiology. North America is characterized by mature infectious disease guidelines, strong stewardship infrastructure, high awareness of community-associated MRSA, and established use of outpatient parenteral antimicrobial therapy for eligible ABSSSI patients. The United States and Canada have advanced emergency care pathways and increasing emphasis on avoiding unnecessary hospital admissions through observation units, long-acting antibiotic approaches, and post-discharge monitoring.

Latin America faces a mixed care environment where urban tertiary centers may have robust infectious disease expertise, while resource variability affects diagnostic access, wound care consistency, and antibiotic stewardship implementation. Brazil and Mexico are important contributors to regional ABSSSI demand due to large patient populations, diabetes prevalence, and urban healthcare utilization. Africa faces the most pronounced diagnostic and access challenges, with ABSSSI management influenced by trauma, limited microbiology infrastructure in some areas, availability of quality-assured antibiotics, and the need for strengthened antimicrobial resistance surveillance. The Middle East is experiencing rising attention to ABSSSI management as diabetes, surgical procedures, and healthcare infrastructure expansion increase the need for coordinated wound infection care; GCC countries are investing in advanced hospital systems and infection control, while broader regional access varies.

Key Group Insights for ABSSSI

NATO countries, while not a healthcare bloc, include many advanced health systems where military medicine, trauma care, field infection control, and readiness planning intersect with ABSSSI management. Lessons from combat wound infection protocols, antimicrobial supply resilience, infection prevention logistics, and mass-casualty readiness can inform broader preparedness for complex skin and soft tissue infections. G7 countries generally lead in clinical research capacity, regulatory standardization, pharmacovigilance, antimicrobial stewardship, and access to advanced diagnostics and therapeutics. Their ABSSSI strategies increasingly emphasize value-based care, outpatient treatment models, real-world evidence on antibiotic effectiveness and safety, and responsible use of broad-spectrum agents.

BRICS countries represent a highly heterogeneous ABSSSI landscape, combining large patient bases, rising chronic disease burdens, substantial surgical and trauma care needs, and varying levels of diagnostic infrastructure. China, India, Brazil, Russia, and South Africa each face distinct resistance and access challenges, making locally adapted treatment pathways, quality-assured antibiotics, and surveillance essential. The European Union provides one of the most structured environments for ABSSSI policy alignment, with antimicrobial resistance surveillance, prescribing stewardship, and regulatory harmonization supporting consistent clinical practice across member states. EU priorities include reducing inappropriate antibiotic use, strengthening cross-border resistance monitoring, and integrating stewardship into hospital accreditation and quality systems.

Within ASEAN, ABSSSI management is shaped by diverse healthcare capacity, tropical climate-related skin infection risks, high patient volumes, and increasing antimicrobial resistance monitoring. Countries with stronger tertiary networks are improving stewardship and wound care protocols, while rural and lower-resource settings continue to face challenges in timely diagnosis, culture access, and continuity of care. The GCC shows growing focus on ABSSSI due to high diabetes prevalence, advanced hospital investment, and demand for effective management of complicated wound infections. Standardized infection prevention, specialist-led antibiotic protocols, outpatient care expansion, and rapid adoption of digital health tools are increasingly relevant across GCC health systems.

Key Country Insights for ABSSSI

China's ABSSSI environment is shaped by large healthcare volumes, expanding stewardship policies, and continued investment in hospital infection control and diagnostics. The United States has a highly developed ABSSSI care environment shaped by community-associated MRSA awareness, emergency department treatment pathways, outpatient parenteral antimicrobial therapy, and strong stewardship expectations. Japan has a mature clinical system with strong regulatory oversight, aging-related skin and wound care needs, and careful antimicrobial governance. India faces high ABSSSI burden due to population scale, diabetes prevalence, trauma exposure, and antimicrobial resistance concerns, making improved diagnostic access and rational antibiotic use central priorities.

Germany benefits from advanced hospital infrastructure, specialist care, and structured surveillance, while the United Kingdom applies strong antimicrobial stewardship principles through national guidance, primary care prescribing governance, and hospital infection control programs. Australia combines high stewardship standards with outpatient care models and public health attention to skin infections in remote and Indigenous communities. France emphasizes antibiotic stewardship and public health campaigns to reduce unnecessary antibiotic use, while South Korea demonstrates advanced hospital capacity, digital health adoption, and strong infection control systems that support rapid diagnosis and standardized management of complicated skin infections.

Italy and Spain face significant burdens related to aging populations, diabetes, surgical site infections, and hospital resource optimization, reinforcing the importance of outpatient management and careful antibiotic selection. Canada emphasizes evidence-based prescribing, infection prevention, and coordinated outpatient care, with regional differences in access across provinces and remote communities. Russia presents a complex landscape where large geography, variable regional infrastructure, and resistance surveillance needs influence ABSSSI care delivery. Brazil's large population, trauma burden, and chronic disease prevalence make wound infection management and stewardship especially important, while Mexico faces substantial ABSSSI demand linked to diabetes, urban healthcare utilization, and variable access to microbiology-guided therapy.

Actionable Recommendations for ABSSSI Industry Leaders

Industry leaders should prioritize ABSSSI strategies that align clinical innovation with antimicrobial stewardship and real-world care delivery. Therapeutic development should focus on clear differentiation in pathogen coverage, safety, dosing convenience, tissue penetration, adherence support, and compatibility with outpatient treatment models. Because unnecessary broad-spectrum exposure contributes to resistance, antibiotic positioning must be supported by robust evidence, microbiological rationale, and guidance on patient selection.

Diagnostic and digital health stakeholders should invest in tools that shorten time to appropriate therapy, improve wound assessment consistency, and support follow-up outside the hospital. Rapid pathogen identification, resistance detection, AI-assisted lesion tracking, and integrated clinical decision support can help reduce treatment failure and avoidable admissions when validated in diverse patient populations. Healthcare providers should expand multidisciplinary ABSSSI pathways that combine emergency medicine, infectious disease, surgery, pharmacy, nursing, and wound care expertise.

Commercial and policy leaders should strengthen education around cellulitis mimics, abscess drainage, diabetic wound infection, MRSA risk assessment, and antibiotic de-escalation. Regional strategies must account for differences in resistance patterns, reimbursement structures, outpatient infusion capacity, and microbiology infrastructure. The most resilient ABSSSI programs will be those that combine access to effective therapy, evidence-based stewardship, patient adherence support, and measurable outcomes such as early clinical response, reduced recurrence, fewer readmissions, and improved wound healing.

Research Methodology

This executive summary is developed through a structured secondary research approach using verified clinical, regulatory, epidemiological, and public health sources. The analysis synthesizes evidence from infectious disease treatment guidelines, antimicrobial resistance surveillance programs, regulatory guidance on ABSSSI clinical trials, peer-reviewed literature, hospital stewardship frameworks, and public health data related to diabetes, wound infections, MRSA, cellulitis, abscess management, and outpatient antibiotic care.

The methodology emphasizes qualitative interpretation rather than market sizing or forecasting. Source evaluation focuses on credibility, recency, clinical relevance, geographic applicability, and consistency across recognized healthcare authorities. Regional, group, and country insights are assessed through healthcare infrastructure indicators, antimicrobial stewardship maturity, diagnostic access, resistance monitoring, chronic disease burden, and care delivery models. Special attention is given to differences between uncomplicated cellulitis, purulent abscesses, surgical site infections, diabetic wound infections, and complicated skin and soft tissue infections.

Analytical outputs are organized to support strategic decision-making for pharmaceutical, diagnostic, healthcare provider, payer, and policy stakeholders. Key themes are validated through triangulation across clinical guidelines, surveillance findings, and real-world care trends. The research intentionally excludes market estimates, market share calculations, and revenue forecasts, focusing instead on evidence-backed drivers, care pathway evolution, regional dynamics, technology impact, and actionable implications for ABSSSI management.

Conclusion

Acute bacterial skin and skin structure infection is evolving from a conventional antibiotic treatment category into a multidisciplinary, technology-enabled, stewardship-driven care priority. Rising antimicrobial resistance, persistent MRSA risk, diabetes-related wound complications, aging populations, and pressure to reduce avoidable hospitalization are reshaping how clinicians diagnose, triage, and treat ABSSSI. The strongest advances are emerging where effective antimicrobial therapy is paired with rapid diagnostics, wound care excellence, outpatient treatment infrastructure, and structured follow-up.

Regional differences remain substantial. Advanced health systems are refining outpatient and digital care models, while emerging and resource-constrained settings continue to prioritize diagnostic capacity, antibiotic quality, surveillance, and equitable access. AI and data-driven tools can improve ABSSSI outcomes when they are clinically validated, integrated into workflows, and aligned with stewardship goals. For industry leaders, the path forward requires evidence-based innovation, responsible antibiotic positioning, and care models that improve early clinical response while limiting resistance pressure.

The future of ABSSSI management will be defined by precision in diagnosis, appropriateness in therapy, efficiency in care delivery, and accountability in outcomes. Stakeholders that address these priorities will be better positioned to support clinicians, improve patient outcomes, and contribute to global efforts against antimicrobial resistance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Acute Bacterial Skin & Skin Structure Infection Market, by End User

  • 7.1. Introduction
  • 7.2. Ambulatory Surgical Centers
  • 7.3. Home Healthcare Settings
  • 7.4. Hospitals

8. Acute Bacterial Skin & Skin Structure Infection Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
  • 8.3. Online

9. Acute Bacterial Skin & Skin Structure Infection Market, by Infection Type

  • 9.1. Introduction
  • 9.2. Cellulitis
  • 9.3. Wound Infections
  • 9.4. Major Cutaneous Abscesses
  • 9.5. Infected Ulcers

10. Acute Bacterial Skin & Skin Structure Infection Market, by Causative Pathogen

  • 10.1. Introduction
  • 10.2. Gram-Positive
  • 10.3. Gram-Negative
  • 10.4. Mixed

11. Acute Bacterial Skin & Skin Structure Infection Market, by Drug Class

  • 11.1. Introduction
  • 11.2. Glycopeptide Antibiotics
  • 11.3. Lipoglycopeptide Antibiotics
  • 11.4. Oxazolidinones
  • 11.5. Lipopeptides

12. Acute Bacterial Skin & Skin Structure Infection Market, by Route of Administration

  • 12.1. Introduction
  • 12.2. Intravenous (IV) Therapy
  • 12.3. Oral Therapy
  • 12.4. Sequential IV-to-Oral Therapy

13. Acute Bacterial Skin & Skin Structure Infection Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Acute Bacterial Skin & Skin Structure Infection Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Acute Bacterial Skin & Skin Structure Infection Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Advanz Pharma Corp. Limited
  • 17.3. Almirall, S.A.
  • 17.4. Astellas Pharma Inc.
  • 17.5. Basilea Pharmaceutica Ltd.
  • 17.6. Bayer Aktiengesellschaft
  • 17.7. Cumberland Pharmaceuticals Inc.
  • 17.8. Dr. Reddy's Laboratories Limited
  • 17.9. Fresenius Kabi AG
  • 17.10. GlaxoSmithKline plc
  • 17.11. Hikma Pharmaceuticals PLC
  • 17.12. Iterum Therapeutics plc
  • 17.13. Lupin Limited
  • 17.14. Melinta Therapeutics, LLC
  • 17.15. Merck KGaA
  • 17.16. Nabriva Therapeutics plc
  • 17.17. Paratek Pharmaceuticals, Inc.
  • 17.18. Sandoz Group AG
  • 17.19. Shionogi & Co., Ltd.
  • 17.20. Spero Therapeutics, Inc.
  • 17.21. Sun Pharmaceutical Industries Limited
  • 17.22. Teva Pharmaceutical Industries Limited
  • 17.23. Venatorx Pharmaceuticals, Inc.
  • 17.24. Viatris Inc.
  • 17.25. Xellia Pharmaceuticals ApS

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HOME HEALTHCARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HOME HEALTHCARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HOME HEALTHCARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELLULITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELLULITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELLULITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL WOUND INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL WOUND INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL WOUND INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MAJOR CUTANEOUS ABSCESSES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MAJOR CUTANEOUS ABSCESSES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MAJOR CUTANEOUS ABSCESSES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFECTED ULCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFECTED ULCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFECTED ULCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GRAM-POSITIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GRAM-POSITIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GRAM-POSITIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GRAM-NEGATIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GRAM-NEGATIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GRAM-NEGATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MIXED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MIXED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MIXED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIPOGLYCOPEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIPOGLYCOPEPTIDE ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIPOGLYCOPEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OXAZOLIDINONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OXAZOLIDINONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OXAZOLIDINONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIPOPEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LIPOPEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIPOPEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRAVENOUS (IV) THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INTRAVENOUS (IV) THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRAVENOUS (IV) THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SEQUENTIAL IV-TO-ORAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SEQUENTIAL IV-TO-ORAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SEQUENTIAL IV-TO-ORAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 115. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 122. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 150. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 172. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 179. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 186. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 200. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 207. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 214. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 221. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 235. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 249. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CAUSATIVE PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 256. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 259. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025